59 related articles for article (PubMed ID: 23846782)
1. Trends in incidence and management of lobular carcinoma in situ: a population-based analysis.
Portschy PR; Marmor S; Nzara R; Virnig BA; Tuttle TM
Ann Surg Oncol; 2013 Oct; 20(10):3240-6. PubMed ID: 23846782
[TBL] [Abstract][Full Text] [Related]
2. UK national survey of management of breast lobular carcinoma in situ.
Chester R; Bokinni O; Ahmed I; Kasem A
Ann R Coll Surg Engl; 2015 Nov; 97(8):574-7. PubMed ID: 26492902
[TBL] [Abstract][Full Text] [Related]
3. Pleomorphic Lobular Carcinoma In Situ: Radiologic-Pathologic Features and Clinical Management.
Flanagan MR; Rendi MH; Calhoun KE; Anderson BO; Javid SH
Ann Surg Oncol; 2015 Dec; 22(13):4263-9. PubMed ID: 25893410
[TBL] [Abstract][Full Text] [Related]
4. Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants.
Chung HL; Middleton LP; Sun J; Whitman GJ
Breast Cancer Res Treat; 2024 Jun; 205(3):545-554. PubMed ID: 38472593
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular disease events within 5 years after a diagnosis of breast cancer.
Mery B; Fouilloux A; Rowinski E; Catella-Chatron J; Guichard JB; Da Costa A; Tinquaut F; Magné N; Bertoletti L
BMC Cancer; 2020 Apr; 20(1):337. PubMed ID: 32398106
[TBL] [Abstract][Full Text] [Related]
6. Short tandem repeat analysis: a practical tool to identify specimen mix-ups in the pathology laboratory.
João D; Cardoso S; Monteiro P; Leal C; Bartosch C
Virchows Arch; 2023 Oct; 483(4):549-554. PubMed ID: 37369928
[TBL] [Abstract][Full Text] [Related]
7. Risk of local failure in breast cancer patients with lobular carcinoma in situ at the final surgical margins: is re-excision necessary?
Sadek BT; Shenouda MN; Abi Raad RF; Niemierko A; Keruakous AR; Goldberg SI; Taghian AG
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):726-30. PubMed ID: 24064317
[TBL] [Abstract][Full Text] [Related]
8. Successful management of bilateral orbital metastases from invasive lobular breast cancer with abemaciclib and letrozole: a case report and literature review.
Rodrigues Alves N; Duarte AF; Ribeiro DF; Silva RS; Carvalho BA; Alpuim Costa D
Front Oncol; 2024; 14():1286910. PubMed ID: 38322413
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of the Breast Cancer Surveillance Consortium Model Among Women with LCIS.
Eroglu I; Sevilimedu V; Park A; King TA; Pilewskie ML
Breast Cancer Res Treat; 2022 Jul; 194(2):257-264. PubMed ID: 35595928
[TBL] [Abstract][Full Text] [Related]
10. The lobular neoplasia enigma: management and prognosis in a long follow-up case series.
Metovic J; Abate SO; Borella F; Vissio E; Bertero L; Mariscotti G; Durando M; Senetta R; Ala A; Benedetto C; Sapino A; Cassoni P; Castellano I
World J Surg Oncol; 2021 Mar; 19(1):80. PubMed ID: 33736652
[TBL] [Abstract][Full Text] [Related]
11. Association of variably methylated tumour DNA regions with overall survival for invasive lobular breast cancer.
Suman M; Dugué PA; Wong EM; Joo JE; Hopper JL; Nguyen-Dumont T; Giles GG; Milne RL; McLean C; Southey MC
Clin Epigenetics; 2021 Jan; 13(1):11. PubMed ID: 33461604
[TBL] [Abstract][Full Text] [Related]
12. Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ.
Dania V; Liu Y; Ademuyiwa F; Weber JD; Colditz GA
Breast Cancer Res; 2019 Nov; 21(1):120. PubMed ID: 31727116
[TBL] [Abstract][Full Text] [Related]
13. The Tyrer-Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS.
Valero MG; Zabor EC; Park A; Gilbert E; Newman A; King TA; Pilewskie ML
Ann Surg Oncol; 2020 Mar; 27(3):736-740. PubMed ID: 31559544
[TBL] [Abstract][Full Text] [Related]
14. A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells.
Beetham H; Chen A; Telford BJ; Single A; Jarman KE; Lackovic K; Luxenburger A; Guilford P
Sci Rep; 2019 Aug; 9(1):12511. PubMed ID: 31467357
[TBL] [Abstract][Full Text] [Related]
15. Surgical Management of Lobular Carcinoma In Situ: Analysis of the National Cancer Database.
Taylor LJ; Steiman J; Schumacher JR; Wilke LG; Greenberg CC; Neuman HB
Ann Surg Oncol; 2018 Aug; 25(8):2229-2234. PubMed ID: 29855831
[TBL] [Abstract][Full Text] [Related]
16. Treatment and survival outcomes of lobular carcinoma
Cheng P; Huang Q; Shou J; Hu G; Han M; Huang J
Oncotarget; 2017 Nov; 8(61):103047-103054. PubMed ID: 29262543
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological characteristics and survival outcomes of invasive lobular carcinoma in different races.
Yang LY; Yang LP; Zhu B
Oncotarget; 2017 Sep; 8(43):74287-74298. PubMed ID: 29088785
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics and Medicinal Chemistry of an External Chinese Herbal Formula for Mammary Precancerous Lesions.
Chen R; Zhang G; Ma Y; Bie F; Fan H; Ma M
Evid Based Complement Alternat Med; 2017; 2017():6235027. PubMed ID: 28811827
[TBL] [Abstract][Full Text] [Related]
19. Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study.
Mullooly M; Khodr ZG; Dallal CM; Nyante SJ; Sherman ME; Falk R; Liao LM; Love J; Brinton LA; Gierach GL
Am J Epidemiol; 2017 Dec; 186(12):1329-1340. PubMed ID: 28637226
[TBL] [Abstract][Full Text] [Related]
20. Risk of second breast cancers after lobular carcinoma in situ according to hormone receptor status.
Mao K; Yang Y; Wu W; Liang S; Deng H; Liu J
PLoS One; 2017; 12(5):e0176417. PubMed ID: 28467490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
